Topigen's TPI ASM8 misses Phase II endpoint

Topigen (Montreal, Quebec) said inhaled TPI ASM8 once daily for 14 days missed the primary endpoint of an allergen-induced maximum decrease in FEV1 for late asthmatic response vs. placebo in the Phase II TPI ASM8-205 trial in 18 patients with mild to moderate asthma. The company said the magnitude of asthmatic response to the allergen challenge was not as large as expected in the placebo group in the double-blind, European study. Topigen expects to begin an additional Phase II dose-finding trial of the compound in the indication this half. ...